Kabaka

Nobody was saying it would be. The headline and article are about production costs at different scales, not prices for anyone buying it after that.

Hill had calculated a generic price of $40 annually last year, but said the interest from generic manufacturers had warranted new analysis. This showed lenacapavir could be mass produced for $35 to $46 a year, if there was annual demand for 2m doses, falling to $25 at scaled up production of 5m to 10m doses each year.

Oh wait, I missed a line where the article actually suggests this…

Dr Hill’s research indicates that this gamechanging innovation could – within a year of launch – be produced and sold for just $25 per person per year.

But you’re right, they won’t sell it for $0 of profit. It would be nice.